Is lamotrigine effective for treating anxiety and depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lamotrigine for Anxiety and Depression

Lamotrigine is NOT a first-line treatment for primary anxiety or unipolar depression, but it has FDA approval and strong evidence for bipolar depression maintenance and shows promise as augmentation therapy for treatment-resistant unipolar depression, particularly when comorbid anxiety is present.

Primary Indications and Evidence Base

Lamotrigine's strongest evidence is in bipolar disorder, not primary anxiety or depression:

  • FDA-approved for maintenance therapy in bipolar disorder 1
  • Effective for preventing depressive episodes in bipolar disorder, with meta-analysis showing lower relapse/recurrence rates compared to placebo (RR 0.84, p=0.037) 2
  • Modest benefit in acute bipolar depression, especially in more severely depressed patients 3

Use in Unipolar Depression

The evidence for unipolar depression is limited and inconsistent:

  • Not recommended as first-line therapy - Second-generation antidepressants (SSRIs, SNRIs) remain the standard based on established guidelines 4, 5
  • May have a role in treatment-resistant depression as augmentation therapy, particularly when:
    • Patients have failed multiple antidepressant trials 6, 7
    • Comorbid anxiety is prominent 6
    • Treatment duration exceeds 8 weeks at adequate doses 6

A systematic review found that benefits in unipolar depression were "inconsistently noted" due to short treatment phases and variable patient populations 6. However, case reports demonstrate marked improvement when added to treatment-resistant cases 7.

Use in Anxiety Disorders

Lamotrigine is NOT established for primary anxiety disorders:

  • No guideline support for anxiety treatment 8
  • Animal studies suggest anxiolytic properties through sodium channel blockade 9
  • Limited human data: One study in epilepsy patients showed reduced anxiety scores (STAI) after 5 weeks 10
  • A case report suggested benefit for PTSD-related chronic stress 11

The evidence is too preliminary to recommend lamotrigine for primary anxiety disorders 3.

Clinical Algorithm for Consideration

Consider lamotrigine when:

  1. Bipolar disorder with prominent depressive episodes (first-line for maintenance) 1, 2
  2. Treatment-resistant unipolar depression after failure of ≥2 adequate antidepressant trials, especially with:
    • Comorbid anxiety symptoms 6
    • Inability to tolerate standard antidepressants
    • Treatment duration planned for >8 weeks 6
  3. Borderline personality disorder with mood instability (emerging evidence) 3, 6

Do NOT use lamotrigine as:

  • First-line treatment for unipolar depression or anxiety
  • Monotherapy for acute anxiety disorders
  • Replacement for established anxiety treatments (SSRIs, SNRIs, CBT)

Critical Caveats

Dermatological Risk

  • Serious rash risk (Stevens-Johnson syndrome) requires slow titration
  • This represents a "major barrier to prescribing" for 15% of psychiatrists 12
  • Mandatory slow dose escalation over weeks to months

Therapeutic Monitoring

  • While 61% of prescribers measure plasma levels, only 22% adjust dosing based on results 12
  • Optimal plasma concentrations for mood disorders remain poorly defined 12
  • Clinical response and adverse effects should guide dosing more than plasma levels

Time to Effect

  • Benefits may require >8 weeks of treatment at adequate doses 6
  • This is longer than typical antidepressant trials

Pregnancy Considerations

  • FDA pregnancy category C (risk cannot be ruled out)
  • Has been used successfully in pregnant patients with bipolar depression and comorbid OCD when other options are limited 13

Bottom Line

For primary anxiety or unipolar depression, start with evidence-based first-line treatments (SSRIs, SNRIs, or CBT) 4, 5. Lamotrigine should be reserved for bipolar disorder maintenance or as a second-step augmentation strategy in treatment-resistant cases with comorbid anxiety, recognizing that the evidence base for these off-label uses remains limited and requires careful patient selection, slow titration, and extended treatment duration to assess benefit.

References

Guideline

practice parameter for the assessment and treatment of children and adolescents with bipolar disorder.

Journal of the American Academy of Child and Adolescent Psychiatry, 2007

Research

Lamotrigine in psychiatric disorders.

The Journal of clinical psychiatry, 2013

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.